Brief Article
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 21, 2014; 20(3): 786-794
Published online Jan 21, 2014. doi: 10.3748/wjg.v20.i3.786
Table 6 Multivariate analysis of overall survival in 44 patients with hepatocellular carcinoma and cirrhosis treated with sorafenib
VariableOS
HR (95%CI)Median OS in weeks (range)P value
ECOG
01 (ref.)50.2 (9.3-153.1)0.031
1-22.36 (1.08-5.16)29.0 (2.9-92.6)
Extrahepatic spread
Absent1 (ref.)45.9 (8.1-153.1)0.059
Present2.41 (0.97-6.01)19.1 (2.9-83)
Portal thrombosis
Absent1 (ref.)45.8 (2.9-153.1)0.015
Present3.33 (1.27-8.72)29.9 (8.1-50)
ALP (U/L)
≤ 1201 (ref.)45.9 (16.6-153.1)0.017
> 1203.13 (1.23-8.00)33.2 (2.9-115.4)
AFP (ng/mL)
≤ 401 (ref.)52.5 (10.7-153.1)0.021
> 402.33 (1.13-4.78)31.0 (2.9-87.4)